Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

immuno-oncology, rare diseases, and autoimmune disorders. Moderna, Inc. (NASDAQ:MRNA) plans to file for approval of three new products this year: a new COVID/flu vaccine, a next-generation COVID ...

Moderna, Inc. engages in the development of ... cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics ...

It looked at differences between patients given a Moderna booster after having had two jabs of the Pfizer vaccine and those who received the Pfizer vaccine three times. While about 70 percent of ...

intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More on MRNA: Moderna NewsMORE Related Stocks ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More on MRNA: Moderna NewsMORE Related Stocks ...

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...

Moderna, Inc. (NASDAQ:MRNA) is an American biotechnology company that discovers, develops, and sells messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno ...

The Spring Covid booster campaign will start on 1 April and run until 17 June. Vaccinations will be offered to: The NHS uses vaccines from two companies across the UK: Pfizer-BioNTech and Moderna.